A study to learn about the amount of asundexian in the blood when healthy participants take different types of asundexian tablets

2023-509447-28-00 Protocol 22665 Human pharmacology (Phase I) - Other Ended

Start 26 Jul 2024 · End 29 Oct 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 22665

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 16
Countries 1
Sites 1

Prevention of ischemic stroke in patients post acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack

Key facts

Sponsor
Bayer AG
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Cardiovascular Diseases [C14]
Trial duration
26 Jul 2024 → 29 Oct 2024
Decision date (initial)
2024-05-17
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Prevention of ischemic stroke in patients post acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack

VersionLevelCodeTermSystem organ class
21.1 LLT 10044391 Transient ischemic attacks 10029205
22.1 PT 10014498 Embolic stroke 100000004852
26.1 PT 10049165 Cerebrovascular accident prophylaxis 100000004865

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Bayer AG

Sponsor organisation
Bayer AG
Address
-
City
Leverkusen
Postcode
51368
Country
Germany

Scientific contact point

Organisation
Bayer AG
Contact name
Therapeutic Area Head

Public contact point

Organisation
Bayer AG
Contact name
Therapeutic Area Head

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 16 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
CRS Clinical Research Services Management GmbH
Clinic, Siemensdamm 65, Siemensstadt, Berlin

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-07-26 2024-10-29 2024-08-07 2024-09-06

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-04-02 Germany Acceptable
2024-05-17
2024-05-17